E2F6 protein levels modulate drug induced apoptosis in cardiomyocytes

Major, Jennifer L.; Salih, Maysoon; Tuana, Balwant S.

doi:10.1016/j.cellsig.2017.09.022

Cited by 11 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…E2F6 , one of the unique E2F family members, is known to be a pRb-independent transcription repressor of E2F -target genes (46). Although the possible links between E2F6 and cell growth control are intriguing, little is known about the regulation mechanism, and the expression pattern and prognostic role of E2F6 in OC are not yet known.…”

Section: Discussionmentioning

confidence: 99%

E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer

Zhou

Zhang

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

E2Fs are a family of pivotal transcription factors. Accumulative evidence indicates that aberrant expression or activation of E2Fs is a common phenomenon in malignances, and significant associations have been noted between E2Fs and tumorigenesis or progression in a wide range of cancers. However, the expression patterns and exact roles of each E2F contributing to tumorigenesis and progression of ovarian cancer (OC) have not yet been elucidated. In this study, we investigated the distinct expression and prognostic value of E2Fs in patients with OC by analyzing a series of databases, including ONCOMINE, GEPIA, cBioPortal, Metascape, and Kaplan–Meier plotter. The mRNA expression levels of E2F1/3/5/8 were found to be significantly upregulated in patients with OC and were obviously associated with tumor stage for OC. Aberrant expression of E2F2/5/7/8 was found to be associated with the clinical outcomes of patients with OC. These results suggest that E2F2/5/8 might serve as potential prognostic biomarkers and targets for OC. However, future studies are required to validate our findings and promote the clinical utility of E2Fs in OC.

show abstract

Section: Discussionmentioning

confidence: 99%

E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer

Zhou

Zhang

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Overexpression of E2F6 in the mouse myocardium leads to cardiomyopathy 21 , which is associated with decreased glycolytic activity and increased expression of β-hydroxybutyrate dehydrogenase, an enzyme that regulates ketone metabolism 22 . In contrast to the deleterious effects of E2F6 overexpression during cardiac development, in vitro studies have shown that E2F6 may protect against cardiotoxic agents 23 . Preclinical studies have shown that microphthalmia transcription factor (MITF) regulates the hypertrophic response of the myocardium 24 , and that the effect of MITF on the myocardial hypertrophic pathway may be mediated epigenetically by the microRNA miR-541 25 .…”

Section: Discussionmentioning

confidence: 99%

Genetic architecture of heart failure with preserved versus reduced ejection fraction

Joseph

Liu²,

Hui³

et al. 2022

Nat Commun

View full text Add to dashboard Cite

Pharmacologic clinical trials for heart failure with preserved ejection fraction have been largely unsuccessful as compared to those for heart failure with reduced ejection fraction. Whether differences in the genetic underpinnings of these major heart failure subtypes may provide insights into the disparate outcomes of clinical trials remains unknown. We utilize a large, uniformly phenotyped, single cohort of heart failure sub-classified into heart failure with reduced and with preserved ejection fractions based on current clinical definitions, to conduct detailed genetic analyses of the two heart failure sub-types. We find different genetic architectures and distinct genetic association profiles between heart failure with reduced and with preserved ejection fraction suggesting differences in underlying pathobiology. The modest genetic discovery for heart failure with preserved ejection fraction (one locus) compared to heart failure with reduced ejection fraction (13 loci) despite comparable sample sizes indicates that clinically defined heart failure with preserved ejection fraction likely represents the amalgamation of several, distinct pathobiological entities. Development of consensus sub-phenotyping of heart failure with preserved ejection fraction is paramount to better dissect the underlying genetic signals and contributors to this highly prevalent condition.

show abstract

“…Although E2F transcription factors are mainly involved in cell cycle regulation, each member has diverse and complex biological functions, and also functions to regulate immune response and substance metabolism [8,9]. Many studies have demonstrated that E2F-like transcription factors play important regulatory roles in the cardiovascular system, and their dysfunction may be associated with multiple cardiovascular diseases [11,12,[20][21][22][23][24][25][26][27]. In addition, different E2F transcription factors have significant effects on the cardiovascular system, such as different regulation of proliferation or apoptosis of vascular smooth muscle cells or cardiomyocytes [13,[28][29][30].…”

Section: Discussionmentioning

confidence: 99%

“…Similar to E2F1, E2F2 is closely related to the function of vascular endothelial cells and cardiomyocytes, and its dysfunction may also be involved in the pathogenesis of various cardiovascular diseases [13,26,30]. Several studies have also shown that E2F3 is closely related to cardiovascular diseases [11][12][13]. E2F3 knockout mice have dysplasia or congestive heart failure, indicating that E2F3 plays an important role in the development of the cardiovascular system or maintenance of its normal functions [14,15].…”

Section: Discussionmentioning

confidence: 99%

Resveratrol Attenuates High Glucose-Induced Vascular Endothelial Cell Injury by Activating the E2F3 Pathway

Ding

Yao

Zhu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is the most common metabolic disease. High glucose-induced macrovascular disease and microangiopathy are major complications of diabetes. E2F3, a member of the E2F transcription factor family, is closely related to cardiovascular diseases. Resveratrol, a nonflavonoid polyphenolic compound widely found in plants, has been shown to have cardiovascular protection. However, there are few studies on whether resveratrol can effectively treat diabetic angiopathy, and the specific mechanism involved needs further study. This study investigated whether E2F3 transcription factors are involved in the process of vascular endothelial injury induced by high glucose and observed its effects on the proliferation of vascular endothelial cells. Then, it analyzed whether resveratrol can inhibit high glucose-induced vascular endothelial cell injury by regulating the E2F3 pathway. We demonstrated that the expression level of the E2F3 transcription factor was significantly inhibited in high glucose state. Resveratrol inhibited high glucose-induced vascular endothelial cell injury by upregulating the E2F3 pathway. High glucose can induce vascular endothelial injury by inhibiting E2F3 gene expression, while resveratrol can inhibit high glucose-induced vascular endothelial injury by activating the E2F3 pathway.

show abstract

E2F6 protein levels modulate drug induced apoptosis in cardiomyocytes

Cited by 11 publications

References 41 publications

E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer

E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer

Genetic architecture of heart failure with preserved versus reduced ejection fraction

Resveratrol Attenuates High Glucose-Induced Vascular Endothelial Cell Injury by Activating the E2F3 Pathway

Contact Info

Product

Resources

About